Overview

The marketing authorisation for Suvaxyn PCV has been withdrawn at the request of the marketing authorisation holder.

български (BG) (489.32 KB - PDF)

View

español (ES) (386.75 KB - PDF)

View

čeština (CS) (439.9 KB - PDF)

View

dansk (DA) (382.9 KB - PDF)

View

Deutsch (DE) (387.93 KB - PDF)

View

eesti keel (ET) (381.59 KB - PDF)

View

ελληνικά (EL) (479.18 KB - PDF)

View

français (FR) (410.53 KB - PDF)

View

hrvatski (HR) (409.78 KB - PDF)

View

italiano (IT) (401.12 KB - PDF)

View

latviešu valoda (LV) (435.17 KB - PDF)

View

lietuvių kalba (LT) (437.33 KB - PDF)

View

magyar (HU) (434.38 KB - PDF)

View

Malti (MT) (440.52 KB - PDF)

View

Nederlands (NL) (386.75 KB - PDF)

View

polski (PL) (441.96 KB - PDF)

View

português (PT) (387.12 KB - PDF)

View

română (RO) (441.28 KB - PDF)

View

slovenčina (SK) (438.7 KB - PDF)

View

slovenščina (SL) (603.23 KB - PDF)

View

Suomi (FI) (381.32 KB - PDF)

View

svenska (SV) (381.87 KB - PDF)

View

Product information

български (BG) (1014.19 KB - PDF)

View

español (ES) (604.97 KB - PDF)

View

čeština (CS) (834.34 KB - PDF)

View

dansk (DA) (670.17 KB - PDF)

View

Deutsch (DE) (634.8 KB - PDF)

View

eesti keel (ET) (616.75 KB - PDF)

View

ελληνικά (EL) (1.01 MB - PDF)

View

français (FR) (658.63 KB - PDF)

View

hrvatski (HR) (707.91 KB - PDF)

View

íslenska (IS) (667.28 KB - PDF)

View

italiano (IT) (729.41 KB - PDF)

View

latviešu valoda (LV) (862.59 KB - PDF)

View

lietuvių kalba (LT) (733.89 KB - PDF)

View

magyar (HU) (856.88 KB - PDF)

View

Malti (MT) (896.54 KB - PDF)

View

Nederlands (NL) (646.88 KB - PDF)

View

norsk (NO) (692.85 KB - PDF)

View

polski (PL) (868.69 KB - PDF)

View

português (PT) (655.54 KB - PDF)

View

română (RO) (739.36 KB - PDF)

View

slovenčina (SK) (882.3 KB - PDF)

View

slovenščina (SL) (841.81 KB - PDF)

View

Suomi (FI) (602.66 KB - PDF)

View

svenska (SV) (599.58 KB - PDF)

View

Latest procedure affecting product information: R/0028

08/04/2020

български (BG) (242.75 KB - PDF)

View

español (ES) (379.79 KB - PDF)

View

čeština (CS) (390.07 KB - PDF)

View

dansk (DA) (396.86 KB - PDF)

View

Deutsch (DE) (384.45 KB - PDF)

View

eesti keel (ET) (392.78 KB - PDF)

View

ελληνικά (EL) (394.81 KB - PDF)

View

français (FR) (379.22 KB - PDF)

View

hrvatski (HR) (380.85 KB - PDF)

View

italiano (IT) (380.63 KB - PDF)

View

latviešu valoda (LV) (393.73 KB - PDF)

View

lietuvių kalba (LT) (385.98 KB - PDF)

View

magyar (HU) (390.68 KB - PDF)

View

Malti (MT) (399.75 KB - PDF)

View

Nederlands (NL) (381.03 KB - PDF)

View

polski (PL) (405.08 KB - PDF)

View

português (PT) (394.55 KB - PDF)

View

română (RO) (385.59 KB - PDF)

View

slovenčina (SK) (388.43 KB - PDF)

View

slovenščina (SL) (388.21 KB - PDF)

View

Suomi (FI) (392.2 KB - PDF)

View

svenska (SV) (395.22 KB - PDF)

View

Product details

Name of medicine
Suvaxyn PCV
Active substance
porcine circovirus recombinant virus (CPCV) 1-2, inactivated
International non-proprietary name (INN) or common name
adjuvanted inactivated vaccine against porcine circovirus type 2 in piglets
Species
Pigs (piglets)
Anatomical therapeutic chemical veterinary (ATCvet) code
QI09AA07

Pharmacotherapeutic group

Immunologicals

Therapeutic indication

Active immunisation of pigs over the age of three weeks against porcine circovirus type 2 (PCV2) to reduce viral load in blood and lymphoid tissues, and the lesions in lymphoid tissues associated with PCV2 infection, as well as to reduce clinical signs - including loss of daily weight gain, and mortality associated with post-weaning multisystemic wasting syndrome.

Authorisation details

EMA product number
EMEA/V/C/000149
Marketing authorisation holder
Zoetis Belgium SA

Rue Laid Burniat 1
1348 Louvain-la-Neuve
Belgium

Marketing authorisation issued
24/07/2009
Revision
13

Assessment history

News on Suvaxyn PCV

This page was last updated on

How useful do you find this page?